Tranilast inhibits hepatic lipid response in nonalcoholic steatohepatitis by deacetylating LKB1

Nonalcoholic fatty liver disease (NAFLD), a progressive hepatic disease with ectopic fat accumulation, can evolve toward nonalcoholic steatohepatitis (NASH). To date, there is still no approved drug therapy, which remains a major unmet need. Previous study has indicated that tranilast ameliorates hepatic fibrosis and stellate cells activation in dietary rat model of NASH. However, the precise mechanism of tranilast in anti-NASH remains unclear. Overall design: we performed a RNA sequencing analysis of liver from high-fat and high-cholesterol(HFHC)compared to HFHC and tranilast subjects